Newly published results from the first head-to-head study between ARICEPT® (donepezil) and Exelon® (rivastigmine) demonstrated that ARICEPT was better tolerated than Exelon in patients with mild to moderate Alzheimer’s disease (AD), allowing more patients on ARICEPT to benefit from treatment.
Almost twice as many patients were able to remain at the maximum effective daily dose of ARICEPT (88 percent vs. 47 percent) due to a lower occurrence of treatment-related side effects. Furthermore, when surveyed, physicians and caregivers significantly favored ARICEPT versus Exelon with respect to satisfaction and ease of use.
Findings from this study are published in the July issue of the peer-reviewed journal, International Journal of Clinical Practice. “It is important to use effective medications that are well tolerated and easy to use, such as ARICEPT, so that Alzheimer’s patients can remain on therapy and sustain the maximum benefit possible over time,” said study investigator David Wilkinson, MD, director of the Memory Assessment and Research Centre, Moorgreen Hospital, Southampton University, Southampton, England.
“Publication of these data provides physicians with very practical clinical information regarding the tolerability and safety of two of the available AD treatments to help them prescribe the most appropriate therapy for their patients.”
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!